ERBB2 and breast cancer: In a phase 3 trial investigating T-DM1 (3.6 mg/kg every 3 weeks) in HER-2-positive breast cancer patients, pneumonitis of any grade occurred in 2.6% of the 743 patients treated with T-DM1 [42].